<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Song Y</submitter><funding>National Research Foundation of Korea</funding><pagination>851</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9913440</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>15(3)</volume><pubmed_abstract>The treatment for hepatocellular carcinoma (HCC), a severe cancer with a very high mortality rate, begins with the surgical resection of the primary tumor. For metastasis or for tumors that cannot be resected, sorafenib, a multi-tyrosine protein kinase inhibitor, is usually the drug of choice. However, typically, neither resection nor sorafenib provides a cure. The drug discovery strategy for HCC therapy is shifting from monotherapies to combination regimens that combine an immuno-oncology agent with an angiogenesis inhibitor. Herbal formulas can be included in the combinations used for this personalized medicine approach. In this study, we evaluated the HCC anticancer efficacy of the new herbal formula, HO-1089. Treatment with HO-1089 inhibited HCC tumor growth by inducing DNA damage-medi</pubmed_abstract><journal>Cancers</journal><pubmed_title>HO-1089 and HO-1197, Novel Herbal Formulas, Have Antitumor Effects via Suppression of PLK1 (Polo-like Kinase 1) Expression in Hepatocellular Carcinoma.</pubmed_title><pmcid>PMC9913440</pmcid><funding_grant_id>NRF-2017M3A9G6068246</funding_grant_id><funding_grant_id>NRF-2021M3A9C4001019</funding_grant_id><pubmed_authors>Kim S</pubmed_authors><pubmed_authors>Lee SY</pubmed_authors><pubmed_authors>Park J</pubmed_authors><pubmed_authors>Seo HR</pubmed_authors><pubmed_authors>Choi I</pubmed_authors><pubmed_authors>Song Y</pubmed_authors><pubmed_authors>Kim N</pubmed_authors></additional><is_claimable>false</is_claimable><name>HO-1089 and HO-1197, Novel Herbal Formulas, Have Antitumor Effects via Suppression of PLK1 (Polo-like Kinase 1) Expression in Hepatocellular Carcinoma.</name><description>The treatment for hepatocellular carcinoma (HCC), a severe cancer with a very high mortality rate, begins with the surgical resection of the primary tumor. For metastasis or for tumors that cannot be resected, sorafenib, a multi-tyrosine protein kinase inhibitor, is usually the drug of choice. However, typically, neither resection nor sorafenib provides a cure. The drug discovery strategy for HCC therapy is shifting from monotherapies to combination regimens that combine an immuno-oncology agent with an angiogenesis inhibitor. Herbal formulas can be included in the combinations used for this personalized medicine approach. In this study, we evaluated the HCC anticancer efficacy of the new herbal formula, HO-1089. Treatment with HO-1089 inhibited HCC tumor growth by inducing DNA damage-medi</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Jan</publication><modification>2025-04-22T04:11:00.209Z</modification><creation>2024-11-09T01:27:18.527Z</creation></dates><accession>S-EPMC9913440</accession><cross_references><pubmed>36765811</pubmed><doi>10.3390/cancers15030851</doi></cross_references></HashMap>